Plain-English translation of NCT06742996 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Mantle Cell Lymphoma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , a new experimental medication, works better when combined with (an existing cancer drug) compared to alone. You would be randomly assigned to receive either the new two-drug combination or the standard drug plus a placebo (an inactive pill). The study will measure how well this treatment works and whether it is safe for people whose mantle cell lymphoma has returned after previous treatments.
Mantle cell lymphoma is a serious blood cancer that often comes back or stops responding to standard treatments. Doctors need better treatment options for patients in this situation, and this trial is testing whether this medication combination can help more people achieve long-term control of their disease.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will randomly receive either the new two-drug combination or the standard drug plus a placebo. You will take pills by mouth regularly and visit the study clinic for check-ups, blood tests, and imaging scans to monitor how well the treatment is working and check for any side effects. The study involves 300 participants across multiple centers, and your specific visit schedule and duration will be explained by the research team during enrollment.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
United States